Rodriguez, E.; Pei, G.; Zhao, Z.; Kim, S.T.; German, A.; Robinson, P.
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871.
https://doi.org/10.3390/cancers13153871
AMA Style
Rodriguez E, Pei G, Zhao Z, Kim ST, German A, Robinson P.
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers. 2021; 13(15):3871.
https://doi.org/10.3390/cancers13153871
Chicago/Turabian Style
Rodriguez, Emma, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German, and Prema Robinson.
2021. "Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis" Cancers 13, no. 15: 3871.
https://doi.org/10.3390/cancers13153871
APA Style
Rodriguez, E., Pei, G., Zhao, Z., Kim, S. T., German, A., & Robinson, P.
(2021). Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers, 13(15), 3871.
https://doi.org/10.3390/cancers13153871